The Vulnerable Plaque: the Real Villain in Acute Coronary Syndromes

被引：22

作者：

Liang, Michael ^{[1
]}

Puri, Aniket ^{[1
,2
]}

Devlin, Gerard ^{[1
]}

机构：

[1] Waikato Hosp, Dept Cardiol, Hamilton, New Zealand

[2] CSM Med Univ, Dept Cardiol, Lucknow, Uttar Pradesh, India

来源：

OPEN CARDIOVASCULAR MEDICINE JOURNAL | 2011年 / 5卷

关键词：

Vulnerable plaque; coronary artery disease;

D O I：

10.2174/1874192401105010123

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The term "vulnerable plaque" refers to a vascular lesion that is prone to rupture and may result in life-threatening events which include myocardial infarction. It consists of thin-cap fibroatheroma and a large lipid core which is highly thrombogenic. Acute coronary syndromes often result from rupture of vulnerable plaques which frequently are only moderately stenosed and not visible by conventional angiography. Several invasive and non-invasive strategies have been developed to assess the burden of vulnerable plaques. Intravascular ultrasound provides a two-dimensional cross-sectional image of the arterial wall and can help assess the plaque burden and composition. Optical coherent tomography offers superior resolution over intravascular ultrasound. High-resolution magnetic resonance imaging provides non-invasive imaging for visualizing fibrous cap thickness and rupture in plaques. In addition, it may be of value in assessing the effects of treatments, such as lipid-lowering therapy. Technical issues however limit its clinical applicability. The role of multi-slice computed tomography, a well established screening tool for coronary artery disease, remains to be determined. Fractional flow reserve (FFR) may provide physiological functional assessment of plaque vulnerability; however, its role in the management of vulnerable plaque requires further studies. Treatment of the vulnerable patient may involve systemic therapy which currently include statins, ACE inhibitors, beta-blockers, aspirin, and calcium-channel blockers and in the future local therapeutic options such as drug-eluting stents or photodynamic therapy.

引用

页码：123 / 129

页数：7

共 49 条

[11] Characterization of plaque components with intravascular ultrasound elastography in human femoral and coronary arteries in vitro [J].

de Korte, CL ;

Pasterkamp, G ;

van der Steen, AFW ;

Woutman, HA ;

Bom, N .

CIRCULATION, 2000, 102 (06) :617-623

[12] The vulnerable patient: Refocusing on the plaque? [J].

Eijgelaar, Wouter J. ;

Heeneman, Sylvia ;

Daemen, Mat J. A. P. .

THROMBOSIS AND HAEMOSTASIS, 2009, 102 (02) :231-239

[13] CORONARY PLAQUE DISRUPTION [J].

FALK, E ;

SHAH, PK ;

FUSTER, V .

CIRCULATION, 1995, 92 (03) :657-671

[14] MECHANISMS LEADING TO MYOCARDIAL-INFARCTION - INSIGHTS FROM STUDIES OF VASCULAR BIOLOGY [J].

FUSTER, V .

CIRCULATION, 1994, 90 (04) :2126-2146

[15]

Fuster V, 1999, LANCET, V353, pSII5

[16] Virtual histology and optical coherence tomography: from research to a broad clinical application [J].

Garcia-Garcia, Hector M. ;

Gonzalo, Nieves ;

Regar, Evelyn ;

Serruys, Patrick W. .

HEART, 2009, 95 (16) :1362-1374

[17] Progression and regression of atherosclerotic lesions - Monitoring with serial noninvasive magnetic resonance imaging [J].

Helft, G ;

Worthley, SG ;

Fuster, V ;

Fayad, ZA ;

Zaman, AG ;

Corti, R ;

Fallon, JT ;

Badimon, JJ .

CIRCULATION, 2002, 105 (08) :993-998

[18] FACTORS OF RISK IN DEVELOPMENT OF CORONARY HEART DISEASE - 6-YEAR FOLLOW-UP EXPERIENCE [J].

KANNEL, WB ;

KAGAN, A ;

STOKES, J ;

DAWBER, TR ;

REVOTSKIE, N .

ANNALS OF INTERNAL MEDICINE, 1961, 55 (01) :33-+

[19] C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis [J].

Kaptoge, Stephen ;

Di Angelantonio, Emanuele ;

Lowe, Gordon ;

Pepys, Mark B. ;

Thompson, Simon G. ;

Collins, Rory ;

Danesh, John ;

Tipping, R. W. ;

Ford, C. E. ;

Pressel, S. L. ;

Walldius, G. ;

Jungner, I. ;

Folsom, A. R. ;

Chambless, L. ;

Ballantyne, C. M. ;

Panagiotakos, D. ;

Pitsavos, C. ;

Chrysohoou, C. ;

Stefanadis, C. ;

Knuiman, M. W. ;

Goldbourt, U. ;

Benderly, M. ;

Tanne, D. ;

Whincup, P. ;

Wannamethee, S. G. ;

Morris, R. W. ;

Kiechl, S. ;

Willeit, J. ;

Mayr, A. ;

Schett, G. ;

Wald, N. ;

Ebrahim, S. ;

Lawlor, D. ;

Yarnell, J. ;

Gallacher, J. ;

Casiglia, E. ;

Tikhonoff, V. ;

Nietert, P. J. ;

Sutherland, S. E. ;

Bachman, D. L. ;

Keil, J. E. ;

Cushman, M. ;

Psaty, B. M. ;

Tracy, R. ;

Tybjaerg-Hansen, A. ;

Nordestgaard, B. G. ;

Zacho, J. ;

Frikke-Schmidt, R. ;

Giampaoli, S. ;

Palmieri, L. .

LANCET, 2010, 375 (9709) :132-140

[20] Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment - Procedural and long-term results [J].

Kereiakes, DJ ;

Szyniszewski, AM ;

Wahr, D ;

Herrmann, HC ;

Simon, DI ;

Rogers, C ;

Kramer, P ;

Shear, W ;

Yeung, AC ;

Shunk, KA ;

Chou, TM ;

Popma, J ;

Fitzgerald, P ;

Carroll, TE ;

Forer, D ;

Adelman, DC .

CIRCULATION, 2003, 108 (11) :1310-1315

← 1 2 3 4 5 →